CVRx announces additional data supporting long-term benefits of barostim

CVRx announced the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These data highlight long-term sustained benefits of Barostim in heart failure patients with reduced ejection fraction. The manuscript is available online at the European Journal of Heart Failure website. CVRx previously announced some of these data as part of expanded labeling granted by FDA on December 23, 2023. The key benefits of Barostim contained in the manuscript include the following: There was not a statistically significant difference in the primary endpoint of CV death and HF hospitalization, demonstrating that the benefits of the therapy do not increase the long-term risk of harm to patients. Patients receiving Barostim + guideline-directed medical therapy had sustained and significant symptomatic improvements at up to 2 years versus those patients receiving GDMT alone; Patients receiving Barostim + GDMT had a 34% reduced likelihood of all-cause death or the need for left ventricular assist device implantation or heart transplant, suggesting a favorable effect of Barostim therapy; Additionally, two new post-hoc analyses of the BeAT-HF trial data, presented on March 5, 2024 at Technology in Heart Failure Therapeutics 2024 in Boston, suggest additional important benefits of Barostim. Dr. William Abraham of the Ohio State Wexner College of Medicine presented analysis showing that patients in the trial with Barostim + GDMT had a 74% reduced risk of receiving advanced heart failure interventions at long-term follow-up versus patients on GDMT alone. Dr. JoAnn Lindenfeld of Vanderbilt University presented analysis showing that patients with Barostim + GDMT had sustained and significant improvements in quality-of-life scores and many subdomains of these scores versus patients on GDMT alone.